Effect of Dabigatran on Referrals to and Switching From Warfarin in Two Academic Anticoagulation Management Services

Author:

Atay Julie K.,Fanikos John,Barnes Geoffrey D.,Ehle Michael,Coatney John,Piazza Gregory,Froehlich James B.,Goldhaber Samuel Z.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference13 articles.

1. The new oral anticoagulants;Garcia;Blood,2010

2. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

3. Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation;Schwartz;Stroke,2010

4. New oral anticoagulants should not be used as first line agents to prevent thromboembolism in patients with atrial fibrillation;Ansell;Circulation,2012

5. United States Food and Drug Administration. Pradaxa (Dabigatran Etexilate Mesylate): Drug Safety Communication—Safety Review of Post-Market Reports of Serious Bleeding Events. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm. Accessed on November 13, 2012.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3